Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial

被引：0
|
作者：
Hida, T. [1 ]
Katayama, R. [2 ]
Nishio, M. [3 ]
Yoshida, T. [4 ]
Kumagai, T. [5 ]
Toyozawa, R. [6 ]
Shimokawaji, T. [7 ]
Goto, K. [8 ]
Nakagawa, K. [9 ]
Seto, T. [10 ]
Yamamoto, N. [11 ]
Asato, T. [12 ]
Hiraoka, K. [13 ]
Zhang, P. [14 ]
Ohe, Y. [15 ]
机构：
[1] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi, Japan
[2] Japanese Fdn Canc Res, Div Expt Chemotherapy, Ctr Canc Chemotherapy, Tokyo, Japan
[3] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Canc Inst Hosp, Tokyo, Japan
[4] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[9] Kindai Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka, Japan
[10] NHO Kyushu Canc Ctr, Thorac Oncol, Fukuoka, Japan
[11] Wakayama Med Univ, Wakayama, Japan
[12] Takeda Pharmaceut Co Ltd, Oncol Therapeut Area Unit Japan & Asia, Tokyo, Japan
[13] Takeda Pharmaceut Co Ltd, Japan Oncol Business Unit, Tokyo, Japan
[14] Millennium Pharmaceut Inc, Cambridge, MA USA
[15] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
brigatinib; alectinib-resistant; ALK-positive NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75.01
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [31] Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC
    Gupta, Neeraj
    Reckamp, Karen L.
    Camidge, David R.
    Kleijn, Huub J.
    Ouerdani, Aziz
    Bellanti, Francesco
    Maringwa, John
    Hanley, Michael J.
    Wang, Shining
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (05): : 1143 - 1154
  • [32] Brigatinib versus crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: results from the phase 3 ALTA-1L trial
    Califano, R.
    Camidge, D.
    Kim, H. -R.
    Ahn, M. -J.
    Yang, J.
    Han, J. -Y.
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W.
    Griesinger, F.
    Felip, E.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    LUNG CANCER, 2020, 139 : S59 - S60
  • [33] Brigatinib in crizotinib-refractory ALK1 NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
    Hochmair, M. J.
    Tiseo, M.
    Reckamp, K. L.
    West, H. L.
    Groen, H. J.
    Langer, C. J.
    Reichmann, W.
    Kerstein, D.
    Kim, D-W.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
    Mok, Tony
    Peters, Solange
    Camidge, D. Ross
    Noe, Johannes
    Gadgeel, Shirish
    Ou, Sai-Hong Ignatius
    Kim, Dong-Wan
    Konopa, Krzysztof
    Pozzi, Emanuela
    Liu, Ting
    Loftin, Isabell R.
    Williams, Crystal
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : 259 - 268
  • [35] Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
    Bernabe-Caro, R.
    Garcia-Campelo, R.
    Garrido, P.
    Palmero, R.
    Artal, A.
    Bayona, C.
    Rodriguez-Abreu, D.
    Lopez-Brea, M.
    Paredes, A.
    Vicente, D.
    Torres, J. M. Sanchez
    Majem, M.
    Diz, P.
    Gordo, R.
    Coca, M.
    de Castro, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S465 - S466
  • [36] Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib A case report
    Nakashima, Koki
    Demura, Yoshiki
    Kurokawa, Kosuke
    Takeda, Toshihiro
    Jikuya, Norihiro
    Oi, Masahiro
    Tada, Toshihiko
    Akai, Masaya
    Ishizuka, Tamotsu
    MEDICINE, 2021, 100 (39) : E27385
  • [37] Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC): Primary results from the J-ALEX study.
    Nokihara, Hiroshi
    Hida, Toyoaki
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Jo, Makoto Nish
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
    Kim, Dong-Wan
    Gadgeel, Shirish
    Gettinger, Scott N.
    Riely, Gregory J.
    Oxnard, Geoffrey R.
    Mekhail, Tarek
    Schmid, Peter
    Dowlati, Afshin
    Heist, Rebecca S.
    Wozniak, Antoinette J.
    Singh, Jatinder
    Cha, Edward
    Spahn, Jessica
    Ignatius, Sai-Hong
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (08):
  • [39] Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.
    Kondo, Masashi
    Sugawara, Shunichi
    Yokoyama, Toshihide
    Kumagai, Toru
    Nishio, Makoto
    Goto, Koichi
    Ohe, Yuichiro
    Seto, Takashi
    Yamamoto, Nobuyuki
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
    Ahn, M.
    Camidge, D. R.
    Tiseo, M.
    Reckamp, K.
    Hansen, K.
    Kim, S.
    Huber, R.
    West, H.
    Groen, H.
    Hochmair, M.
    Leighl, N.
    Gettinger, S.
    Langer, C.
    Paz-Ares, L.
    Smit, E.
    Kim, E.
    Reichmann, W.
    Kerstein, D.
    Kim, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
12345